CLINICAL RESULTS OF CEFUROXIME (CXM) THERAPY IN PEDIATRIC INFECTIONS

Cefuroxime, a new cephalosporin C antibiotic, was administered to 15 children with respiratory tract infection, urinary tract infection, or subcutaneous tumour. The following results were obtained. 1) CXM 30-100mg/kg/day were used in treatment of respiratory tract infection. Eight of the eleven pati...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1979/11/25, Vol.32(11), pp.1132-1136
Main Authors: NAKAMURA, YUKIYOSHI, YANAGISAWA, KOJI, ICHIHASHI, HARUO
Format: Article
Language:Japanese
Subjects:
Bacterial Infections - drug therapy
Bacterial Infections - microbiology
Cefuroxime - pharmacology
Cefuroxime - therapeutic use
Cephalosporins - therapeutic use
Child
Child, Preschool
Drug Resistance, Microbial
Escherichia coli - drug effects
Female
Haemophilus influenzae - drug effects
Humans
Infant
Infant, Newborn
Male
Respiratory Tract Infections - drug therapy
Respiratory Tract Infections - microbiology
Staphylococcus aureus - drug effects
Streptococcus - drug effects
Urinary Tract Infections - drug therapy
Urinary Tract Infections - microbiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cefuroxime, a new cephalosporin C antibiotic, was administered to 15 children with respiratory tract infection, urinary tract infection, or subcutaneous tumour. The following results were obtained. 1) CXM 30-100mg/kg/day were used in treatment of respiratory tract infection. Eight of the eleven patients treated responded to the therapy. 2) CXM 45-75mg/kg/day were given to 3 patients with urinary tract infection. Excellent results were obtained in all these cases. 3) One patient with subcutaneous tumour responded to CXM therapy. 4) Clinical isolates from the foci involved, i. e., Staphylococcus aureus(4 strains), Group A Streptococcus hemolyticus(1 strain), Streptococcus pneumoniae(1 strain), Haemophilus influenzae(1 strain), and Escherichia cola(3 strains) were all eliminated by CXM therapy except 2 unassessable strains. 5) No noteworthy side effect was noted.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.32.1132